gms | German Medical Science

64. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

26. - 29. Mai 2013, Düsseldorf

A current series of surgically treated hormone-active microadenomas treated at a single center

Meeting Abstract

  • Roman Rotermund - Klinik und Poliklinik für Neurochirurgie, Universitätsklinikum Hamburg-Eppendorf
  • Till Burkhardt - Klinik und Poliklinik für Neurochirurgie, Universitätsklinikum Hamburg-Eppendorf
  • Manfred Westphal - Klinik und Poliklinik für Neurochirurgie, Universitätsklinikum Hamburg-Eppendorf
  • Jörg Flitsch - Klinik und Poliklinik für Neurochirurgie, Universitätsklinikum Hamburg-Eppendorf

Deutsche Gesellschaft für Neurochirurgie. 64. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC). Düsseldorf, 26.-29.05.2013. Düsseldorf: German Medical Science GMS Publishing House; 2013. DocMI.08.07

doi: 10.3205/13dgnc346, urn:nbn:de:0183-13dgnc3467

Veröffentlicht: 21. Mai 2013

© 2013 Rotermund et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Objective: This is a retrospective study of patients who were treated for microadenomas between 2008 and 2012 at a single center. The objective was to determine remission and complication rates and complications.

Method: We conducted a retrospective data base research, focusing on diagnosis, early remission and surgery-related complications.

Results: 976 patients underwent transsphenoidal surgery for pituitary adenomas of various kinds. 333 patients were diagnosed as hormone-producing adenoma prior to the operation. 26 patients were diagnosed with microprolactinoma, with a primary remission rate of 92%, 39 patients were diagnosed with GH-producing microadenoma with a remission rate of 89% (in cases of primary operation) and 50% in cases of a secondary operation. Cushing’s disease was existent in 109 patients with remission rates of 92% in cases of primary therapy, 64% in cases of secondary and a remission rate of 60% in cases of tertiary surgical therapy. One patient underwent a fourth operation and did not go into remission after surgery. 5 patients were diagnosed with micro-TSHoma and had a remission rate of 100%. Epistaxis was the most common complication (n=9), followed by transient diabetes insipidus (n=7), SIADH (n=6) and partial anterior insufficiency (n=5), other complications such as complete pituitary insufficiency (n=1), sinusitis (n=1) and pulmonary embolism (n=1) were very uncommon. There was no mortality in surgery for microadenomas in this series.

Conclusions: High remission rates after surgery for microadenomas are achievable and present a realistic goal of transsphenoidal surgery, complications are mostly pituitary related and do usually not pose a major threat to the patients' health.